Wegovy and Ozempic are popular injectable drugs for weight loss and type 2 diabetes, yet oral alternatives are hindered by scientific and logistical challenges. Pfizer halted trials for danuglipron after a liver injury was reported. The only available oral GLP-1 drug, Rybelsus, is often overlooked despite its approval for diabetes treatment. It requires daily dosing, unlike the weekly injections of Ozempic, and its lack of weight-loss approval limits its market visibility. As researchers explore oral options, the quest for a convenient pill form continues against significant barriers.
Pfizer's recent decision to discontinue trials for its oral GLP-1 drug highlights the complexities in developing alternatives to the widely-used injectable versions of these medications.
Rybelsus, the first oral GLP-1 approved for type 2 diabetes, lacks the same attention as weight-loss injections, reflecting the gap in public awareness.
Collection
[
|
...
]